(VIANEWS) – EnLink Midstream, LLC (ENLC), Gilead Sciences (GILD), ASML Holding (ASML) are the highest payout ratio stocks on this list.
We have congregated information about stocks with the highest payout ratio so far. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. EnLink Midstream, LLC (ENLC)
111.49% Payout Ratio
EnLink Midstream, LLC provides midstream energy services in the United States. It operates through Permian, Louisiana, Oklahoma, North Texas, and Corporate segments. The company is involved in gathering, compressing, treating, processing, transporting, storing, and selling natural gas; fractionating, transporting, storing, and selling natural gas liquids; and stabilizing, trans-loading , and condensate crude oil , as well as providing brine disposal services. Its midstream energy asset network includes approximately 12,100 miles of pipelines; 22 natural gas processing plants;7 fractionators with approximately 320,000 barrels per day; barge and rail terminals; product storage facilities; brine disposal wells; and a crude oil trucking fleet. The company was incorporated in 2013 and is based in Dallas, Texas.
Earnings Per Share
As for profitability, EnLink Midstream, LLC has a trailing twelve months EPS of $-0.85.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.35%.
2. Gilead Sciences (GILD)
88.07% Payout Ratio
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Earnings Per Share
As for profitability, Gilead Sciences has a trailing twelve months EPS of $0.24.
PE Ratio
Gilead Sciences has a trailing twelve months price to earnings ratio of 350.25. Meaning,
the purchaser of the share is investing $350.25 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.58%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Sep 13, 2022, the estimated forward annual dividend rate is 2.92 and the estimated forward annual dividend yield is 4.2%.
Sales Growth
Gilead Sciences’s sales growth is negative 12.4% for the current quarter and negative 5.7% for the next.
3. ASML Holding (ASML)
49.5% Payout Ratio
ASML Holding N.V. develops, produces, markets, sells, and services advanced semiconductor equipment systems consisting of lithography, metrology, and inspection related systems for memory and logic chipmakers. The company provides extreme ultraviolet lithography systems; and deep ultraviolet lithography systems comprising immersion and dry lithography solutions to manufacture various range of semiconductor nodes and technologies. It also offers metrology and inspection systems, including YieldStar optical metrology solutions to measure the quality of patterns on the wafers; and HMI e-beam solutions to locate and analyze individual chip defects. In addition, the company provides computational lithography and software solutions to create applications that enhance the setup of the lithography system; and mature products and services that refurbish used lithography equipment and offers associated services. It operates in Japan, South Korea, Singapore, Taiwan, China, the Netherlands, Europe, the United States, and rest of Asia. The company was formerly known as ASM Lithography Holding N.V. and changed its name to ASML Holding N.V. in 2001. ASML Holding N.V. was founded in 1984 and is headquartered in Veldhoven, the Netherlands.
Earnings Per Share
As for profitability, ASML Holding has a trailing twelve months EPS of $12.96.
PE Ratio
ASML Holding has a trailing twelve months price to earnings ratio of 52.25. Meaning,
the purchaser of the share is investing $52.25 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 57.37%.
Moving Average
ASML Holding’s worth is way higher than its 50-day moving average of $603.58 and way higher than its 200-day moving average of $533.38.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 153.1% and 28.4%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.2%, now sitting on 19.73B for the twelve trailing months.
4. Novo Nordisk A/S (NVO)
46.51% Payout Ratio
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Earnings Per Share
As for profitability, Novo Nordisk A/S has a trailing twelve months EPS of $2.92.
PE Ratio
Novo Nordisk A/S has a trailing twelve months price to earnings ratio of 47.59. Meaning,
the purchaser of the share is investing $47.59 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 72.19%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 24.9%, now sitting on 157.25B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 6.2% and 11.3%, respectively.
Sales Growth
Novo Nordisk A/S’s sales growth is 16.6% for the present quarter and 11.6% for the next.
Volume
Today’s last reported volume for Novo Nordisk A/S is 1813050 which is 28.97% above its average volume of 1405730.
5. MVB Financial Corp. (MVBF)
45.83% Payout Ratio
MVB Financial Corp., together with its subsidiaries, provides banking and mortgage products and services to individuals and corporate clients in the United States. The company operates through three segments: Commercial and Retail Banking; Mortgage Banking; and Financial Holding Company. It offers various demand deposit accounts, savings accounts, money market accounts, and certificates of deposit; and grants various types of loans, including commercial and commercial real estate loans, residential real estate loans, home equity lines of credit, and consumer loans. The company also provides debit cards; cashier's checks; safe deposit rental facilities; and non-deposit investment services, as well as automated teller machines, and internet and telephone banking services. The company operates 13 full-service banking branches; ten offices in West Virginia; and three in Virginia. MVB Financial Corp. was founded in 1997 and is headquartered in Fairmont, West Virginia.
Earnings Per Share
As for profitability, MVB Financial Corp. has a trailing twelve months EPS of $1.44.
PE Ratio
MVB Financial Corp. has a trailing twelve months price to earnings ratio of 14.65. Meaning,
the purchaser of the share is investing $14.65 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.97%.
Yearly Top and Bottom Value
MVB Financial Corp.’s stock is valued at $21.10 at 07:23 EST, way under its 52-week high of $44.22 and above its 52-week low of $20.64.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.1%, now sitting on 140.6M for the twelve trailing months.
Sales Growth
MVB Financial Corp.’s sales growth is 12.8% for the present quarter and 44.1% for the next.
Moving Average
MVB Financial Corp.’s worth is below its 50-day moving average of $22.89 and way under its 200-day moving average of $30.38.
6. Nike (NKE)
34.66% Payout Ratio
NIKE, Inc., together with its subsidiaries, designs, develops, markets, and sells men's, women's, and kids athletic footwear, apparel, equipment, and accessories worldwide. The company provides athletic and casual footwear, apparel, and accessories under the Jumpman trademark; and casual sneakers, apparel, and accessories under the Converse, Chuck Taylor, All Star, One Star, Star Chevron, and Jack Purcell trademarks. In addition, it sells a line of performance equipment and accessories comprising bags, socks, sport balls, eyewear, timepieces, digital devices, bats, gloves, protective equipment, and other equipment for sports activities under the NIKE brand; and various plastic products to other manufacturers. The company markets apparel with licensed college and professional team, and league logos, as well as sells sports apparel. Additionally, it licenses unaffiliated parties to manufacture and sell apparel, digital devices, and applications and other equipment for sports activities under NIKE-owned trademarks. The company sells its products to footwear stores; sporting goods stores; athletic specialty stores; department stores; skate, tennis, and golf shops; and other retail accounts through NIKE-owned retail stores, digital platforms, independent distributors, licensees, and sales representatives. The company was formerly known as Blue Ribbon Sports, Inc. and changed its name to NIKE, Inc. in 1971. NIKE, Inc. was founded in 1964 and is headquartered in Beaverton, Oregon.
Earnings Per Share
As for profitability, Nike has a trailing twelve months EPS of $2.14.
PE Ratio
Nike has a trailing twelve months price to earnings ratio of 60.59. Meaning,
the purchaser of the share is investing $60.59 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 37.39%.
Sales Growth
Nike’s sales growth for the current quarter is 10.4%.
Moving Average
Nike’s value is way higher than its 50-day moving average of $106.46 and way above its 200-day moving average of $109.98.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Sep 1, 2022, the estimated forward annual dividend rate is 1.22 and the estimated forward annual dividend yield is 1.33%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 3.6%, now sitting on 47.15B for the twelve trailing months.
